Cargando…

Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?

VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its der...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agazzi, A, Sammassimo, S, Laszlo, D, Liptrott, SJ, Cascio, R, Alietti, A, Rabascio, C, Mancuso, P, Pruneri, G, Martinelli, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223996/ https://www.ncbi.nlm.nih.gov/pubmed/22276003 http://dx.doi.org/10.3332/ecancer.2009.136

Ejemplares similares

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
por: He, Gan-Lin, et al.
Publicado: (2018)

(333) Transitioning Vad Care: Outcomes of Virtual Vad Follow Up Visits
por: Meehan, K., et al.
Publicado: (2023)

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020)

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma – a case report
por: Gruszka, Alicja M., et al.
Publicado: (2015)

Work for the V.A.D.s.
Publicado: (1919)

The Victimisation of V.A.D.s.
por: Green, J. E.
Publicado: (1919)

Editorial: Hemostasis in ECMO and VAD
por: Teruya, Jun, et al.
Publicado: (2019)

The Victimisation of V.A.D.s.
Publicado: (1919)

To VAD or Not to VAD: A Case of Durable Left Ventricular Assist Device Implantation in a COVID-19 Patient
por: Ignaszewski, M., et al.
Publicado: (2021)

The Control of V.A.D. Hospitals
Publicado: (1918)

Thrombolytics in VAD management — A single-center experience
por: Nair, N., et al.
Publicado: (2016)

Some Difficulties with V.A.D. Workers
Publicado: (1916)

Some Difficulties with V.A.D. Workers
Publicado: (1916)

V.A.D.'s Casualty Clearing Stations
Publicado: (1919)

Joint Women's V.A.D. Department
por: Oliver, B. C.
Publicado: (1919)

VAD Patients’ Perception of Potential Telemedicine Support
por: Berg, Thomas, et al.
Publicado: (2022)

Editorial: Hemostasis in ECMO and VAD, volume II
por: Teruya, Jun, et al.
Publicado: (2023)

The Payment of Medical Officers in V.A.D. Hospitals
Publicado: (1917)

More V.A.D.s of All Ranks Wanted
por: Stanley, Arthur, et al.
Publicado: (1916)

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis
por: Gardellini, A, et al.
Publicado: (2013)

The effect of captopril on the performance of the control strategies of BJUT-II VAD
por: Gu, Kaiyun, et al.
Publicado: (2016)

The role of VosA/VelB-activated developmental gene vadA in Aspergillus nidulans
por: Park, Hee-Soo, et al.
Publicado: (2017)

Thoratec Centrimag VAD for cardiogenic shock – a developing country experience
por: Villavicencio, M, et al.
Publicado: (2013)

Hemostatic Challenges in Pediatric Critical Care Medicine—Hemostatic Balance in VAD
por: Ghbeis, Muhammad Bakr, et al.
Publicado: (2021)

On the function of biosynthesized cellulose as barrier against bacterial colonization of VAD drivelines
por: Kaemmel, Julius, et al.
Publicado: (2021)

The caspase inhibitor zVAD increases lung inflammation in pneumovirus infection in mice
por: van den Berg, Elske, et al.
Publicado: (2015)

Implantable ventricular assistance systems (VAD) as a bridge to transplant or as ‘destination therapy’
por: Nesta, Marialisa, et al.
Publicado: (2021)

Laser-Treated Surfaces for VADs: From Inert Titanium to Potential Biofunctional Materials
por: Bock, Eduardo, et al.
Publicado: (2022)

An essential role for the VASt domain of the Arabidopsis VAD1 protein in the regulation of defense and cell death in response to pathogens
por: Khafif, Mehdi, et al.
Publicado: (2017)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Proper Left Ventricular Assist Device Outpatients Monitoring: VAD Coordinator Interface Despite COVID-19 Pandemic
por: Boschi, S., et al.
Publicado: (2021)

Communication skills and raising awareness in clinical practice: an Italian experience
por: Liptrott, S, et al.
Publicado: (2009)

Robust Audio Content Classification Using Hybrid-Based SMD and Entropy-Based VAD
por: Wang, Kun-Ching
Publicado: (2020)

A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion
por: Ferrari, Aldo, et al.
Publicado: (2020)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
por: Cerchione, C., et al.
Publicado: (2022)

Genome Wide Analysis Reveals the Role of VadA in Stress Response, Germination, and Sterigmatocystin Production in Aspergillus nidulans Conidia
por: Son, Ye-Eun, et al.
Publicado: (2020)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Double filtration plasmapheresis in a dog with multiple myeloma and hyperviscosity syndrome
por: Lippi, I., et al.
Publicado: (2015)

Effects of Z-VaD-Ala-Asp-Fluoromethyl Ketone (Z-VAD-FMK) and Acetyl-Asp-Glu-Val-Asp-Aldehyde(Ac-DEVD-CHO) on Inflammation and Mucus Secretion in Mice Exposed to Cigarette Smoke
por: He, Mudan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m92hg4cfqug66ju68u47od9k2m